UBS maintains XP at Buy, lowers price target to $23 from $37

What happened

UBS maintained its Buy rating on XP but cut its price target to $23 from $37, a 37.8% reduction. The new target implies 55.6% upside from XP’s Nov. 5 closing price of $14.78. Recent analyst targets listed for XP ranged from $15 to $38.

Confirmed

Global impact / market context

A lower target signals that UBS now sees less value in XP than before, even while keeping its Buy rating. The change may shape investor expectations and positioning, while the stated upside still depends on XP’s share price reaching UBS’s estimate.

Analyst inference

Other recent analyst targets in the article span $15 to $38, so UBS’s revised $23 estimate sits within that range. The spread shows differing views of XP’s value; analyst targets are estimates, not guaranteed outcomes or company results.

Confirmed

What to watch

1. Compare future XP analyst updates with UBS’s $23 target and the listed $15-to-$38 range to see whether estimates converge or remain widely different. Analyst inference
2. Check whether UBS changes its Buy rating or target again; the article reports a lower target but gives no reason for the reduction. Analyst inference
3. Track XP’s share price against the $14.78 Nov. 5 close and UBS’s $23 target, while treating the implied upside as an estimate rather than a forecast guarantee. Analyst inference

Evidence

• Original source link unavailable